SARMS Powder AC-262536 (870888-46-3) for bodybuilding

www.wisepowder.com

wise12@wisepowder.com

SARMS Powder AC-262536 (870888-46-3) for bodybuilding Overview AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM).AC-262536 is a powerful SARM that could add a lot of value to your performance and overall results. No clinical trials have been done on this SARM yet and only a select number of bodybuilders and athletes have tried it.

1/5

www.wisepowder.com

wise12@wisepowder.com

Base Information Name

AC-262536

CAS

870888-46-3

Purity

98%

Chemical name

AC-262536 CHEMBL468938 SCHEMBL4879629 SCHEMBL18994034 BDBM50258791 4-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-1-naphthonitrile

Synonyms

4-(3-exo-Hydroxy-8-azabicyclo[3.2.1]oct-8-yl)naphthalene-1-c arbonitrile

Molecular Formula

C18H18N2O

Molecular Weight

278.355 g/mol

Melting Point

158 to 162°C

InChI Key

ATKWLNSCJYLXPF-FICVDOATSA-N

Form

Solid

Appearance

White

Half Life

unknown

Solubility

soluable in ethanol

Storage Condition

Store at dry and clean room temperature, in a sealed airtight container, keep the air out, protected from heat, light and humidity.

Application

AC-262536 represents a novel class of selective androgen receptor modulators (SARMs) with beneficial anabolic effects.

Testing Document

Available

AC-262536 (870888-46-3) General Description AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM).AC-262536 is a powerful SARM that could add a lot of value to your performance and overall results. No clinical trials have been done on this SARM yet and only a select number of bodybuilders and athletes have tried it.Research shows that AC-262 provides more than 60% of the anabolic benefits that you’d get from taking testosterone, with only 27% of the androgenic activity.

2/5

www.wisepowder.com

wise12@wisepowder.com

Therefore, it’s safe to say that AC-262 has an anabolic: androgenic ratio of 2.45:1.But,this doesn’t mean that AC-262 won’t have any androgenic effects at all, because it’s a SARM after all.

AC-262536 (870888-46-3) History AC-262536 is a selective androgen receptor modulator (SARM). AC-262536 was created and introduced to the market by ACADIA Pharmaceuticals in San Diego, California.

SARMs are synthetic ligands (usually non-steroidal) that ideally act as a full agonist on anabolic organs (creating desirable effects on muscle and bone) Initial research on this SARM started in 2007 with animal studies and there have been no human trials or studies done on it since.

Nevertheless, the available data from animal studies show that AC-262536 can protect the user against diseases like Alzheimer’s and prostate cancer while promoting sustainable muscle growth.

AC-262536 (870888-46-3) Mechanism Of Action AC-262536 works similarly to other SARMs because it interacts with androgen receptors in the bones and muscles without affecting sexual tissue. The body’s androgen receptor (AR) typically affects human sexual development, but once it has been activated by compounds like testosterone it can affect other parts of the body like the liver, muscles, bones and even the central nervous system.

The thing is that targeting AR signaling by taking testosterone comes with side-effects that impact the sex tissues. This means that in addition to developing strong bones and bigger muscles, you’ll also have an increased prostate cancer risk and shrinking testicles, while female bodybuilders can also experience an enlarged clitoris.

Unlike other SARMs, AC-262536 avoids this by binding directly with the androgen receptor.

As a result, it activates the androgen receptor specifically in the cells that make up your bones and muscles without affecting sexual tissue or your liver enzymes.

AC-262536 (870888-46-3) Application 3/5

www.wisepowder.com

wise12@wisepowder.com

Acts On Pituitary Function AC-262536 can bind to androgen receptors and suppress luteinizing hormone (LH) stronger than testosterone in animal models.

AC-262536 also can restored AR levels in castrated rats.

Helps With Muscle Growth AC-262536 can improve muscle growth similarly to testosterone For example, mice injected with AC had muscle growth achieving 66% of the maximum effect reached with testosterone.

May Help Against Prostate Cancer AC-262536 may have benefits for prostate cancer as it can strongly antagonize the effects of dihydroxytestosterone (DHT) in the human prostate cancer cell (in vitro).

May Help With Alzheimer’s Disease In APOE4 positive animals, AC-262536 was able to restore some cognitive abilities by action on the hippocampus.

AC-262536 (870888-46-3) More research Because of the limitations and liabilities of current testosterone therapies, non-steroidal tissue-selective androgen receptor modulators may provide a clinically meaningful advance in therapy. Using a functional cell-based assay AC-262536 was identified as a potent and selective AR ligand, with partial agonist activity relative to the natural androgen testosterone. A 2-week chronic study in castrated male rats indicated that AC-262536 significantly improves anabolic parameters in these animals, especially in stimulating the growth of the levator ani and in suppressing elevated LH levels. In sharp contrast to testosterone, AC-262536 has weak androgenic effects, as measured by prostate and seminal vesicle weights. Thus, AC-262536 represents a novel class of selective androgen receptor modulators (SARMs) with beneficial anabolic effects.

AC-262536 (870888-46-3) Document Download coa

4/5

www.wisepowder.com

wise12@wisepowder.com

AC-262536 (870888-46-3) Reference [1]Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator.

Piu F, et al. J Steroid Biochem Mol Biol. 2008.

[2] Piu, F; Gardell, LR; Son, T; Schlienger, N; Lund, BW; Schiffer, HH; Vanover, KE; Davis, RE; Olsson, R; Bradley, SR (2008). “Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator”. The Journal of Steroid Biochemistry and Molecular Biology.

109 (1–2): 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613

5/5